金吾财讯 | 德国医疗保健和材料集团默克集团周一表示，将以 39 亿美元的股权价值收购美国生物科技公司 SpringWorks Therapeutics，以增强其抗癌药物业务。扣除 SpringWorks 的现金持有量后，企业价值相当于 34 亿美元（30 亿欧元）。默克集团在一份声明中表示，此次交易将以现有现金和新债务为资金来源，预计将在2027年增加默克经特殊项目调整后的每股收益。该集团还补充称，其仍将有能力进行更大规模的交易。总部位于康涅狄格州斯坦福的 SpringWorks 公司于 2019 年在纽约上市，致力于开发治疗癌症和罕见肿瘤的药物。该公司在市场上有两种产品：Ogsiveo，2024 年销售额为 1.72 亿美元，用于治疗一种影响软组织的恶性肿瘤；以及 Gomekli，于 2 月获批用于治疗以神经鞘瘤为特征的 NF1-PN。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.